Harrow Stock Plunges 10.77% on Earnings Miss

On May 9, 2025, Harrow's stock experienced a significant drop of 10.77% in pre-market trading, reflecting a challenging start to the day for the pharmaceutical and drug compounding company.

Harrow reported a quarterly loss of $0.38 per share, significantly missing the consensus estimate of $0.02. This loss is a deterioration from the previous year's loss of $0.28 per share. The company's revenue for the quarter ended March 2025 was $47.83 million, falling short of the consensus estimate by 19.88%. This revenue figure also represents a decline from the year-ago revenues of $34.59 million.

Despite the disappointing earnings report, Harrow has shown mixed performance in meeting earnings estimates over the past four quarters, surpassing expectations twice. The company's stock has declined by approximately 26.7% since the beginning of the year, outperforming the broader market's decline of 4.3%.

Investors are now looking ahead to see how Harrow's stock will perform in the coming quarters. The company's earnings outlook, including current consensus earnings expectations and recent changes in these expectations, will be crucial in determining future stock movements. The current consensus EPS estimate for the coming quarter is $0.13 on $68.63 million in revenues, with a fiscal year estimate of $0.47 on $286.4 million in revenues.